Finally, the open‐label phase 2 DESTINY‐Lung01 study evaluated trastuzumab deruxtecan in 91 nonsquamous metastatic NSCLC patients harboring ERBB2 mutations that relapsed during standard treatment or had refractory to standard treatment (platinum‐based chemotherapy, anti‐PD‐1 or anti‐PD‐L1 treatment), and reported an ORR in 55% of the patients.4 Here, ERBB2 is linked to non-small cell lung carcinoma.